Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial

By afschroeder • August 14, 2025

Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR 3rd, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA. 2025 Aug 13. doi: 10.1001/jama.2025.12543. Epub ahead of print. PMID: 40802264.

Tags: Harbor UCLA, Infectious Diseases, Publications

Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease

Lenell J, Flores Tomasino G, Han D, Wolny R, Park C, Grodecki K, Kwiecinski J, Xing E, Manral N, Asebiomo F, Goyal D, Calsavara VF,[...]

Coronary Artery Calcium in ACC/AHA Prevention Guidelines: Evolution From 2007 to 2026

Irannejad K, Mora R, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Coronary Artery Calcium in ACC/AHA Prevention Guidelines: Evolution From 2007 to 2026. JACC[...]

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]